ESMO Media Releases

Women living and working in places with higher levels of fine particle air pollution are more likely to get breast cancer than those living and working in less polluted areas

Results from highly anticipated phase 3 clinical trials in gynaecological cancers with, among others, new data that cover the entire spectrum of managing patients with cervical cancer, will be presented at the ESMO Congress 2023 in Madrid, Spain

More people with non-small cell lung cancer (NSCLC) are likely to benefit from new drugs that target molecular alterations in tumour cells, with less need for chemotherapy, following results of multiple landmark clinical trials reported for the first time in late-breaking presentations at the ESMO Congress 2023  

Artificial intelligence (AI) has made a grand entrance into the public debate this year, but researchers have long been investigating its potential to transform cancer care and improve patient outcomes

Under the promise to “Disseminating innovative research for optimal cancer care” as this year’s tagline reads, the ESMO Congress 2023 will be held in Madrid between 20-24 October 2023 with a virtual component to allow as many people as possible to attend.

The Molecular Analysis for Precision Oncology Congress 2023 (MAP) is the appointment where experts present the latest developments and discuss the present and future of the rapidly evolving field of precision oncology, whose aim is to identify genomic alterations to provide the best possible personalised treatment to patients with cancer. 

The new online tool comes in an interactive, concise, and updatable visual format to support practicing oncologists in the rapidly evolving medical field

The ESMO Breast Cancer Congress 2023, will be held onsite in Berlin, Germany, and online, through a virtual platform, between 11-13 May 2023

Adding immunotherapy to standard chemotherapy for first-line treatment of advanced or first recurrence of endometrial cancer significantly improves progression-free survival (PFS) compared to chemotherapy alone, with a promising early indication of improved overall survival (OS)

ESMO is pleased to announce a combination of brand-new and well-established events happening in March, tackling two specific areas of oncology, with leading experts discussing novel clinical data and the latest treatment options

A total of 1,261,990 people will die from cancer in 2023 in the EU (EU-27). A further 172,314 people will die from the disease in the UK, according to new research published in the leading cancer journal Annals of Oncology today 

The ESMO Targeted Anticancer Therapies Congress 2023, the gathering focusing on promising new anticancer targets and agents, with a particular emphasis on those in early phase clinical development, will be held in Paris, France, on 6-8 March 2023.